Entera Bio (ENTX) Total Debt (2017 - 2026)
Entera Bio's (ENTX) quarterly Total Debt came in at $567000.0 in Q1 2026, up 10.1% YoY from $515000.0 in Q1 2025, and up 44.27% on a QoQ basis from $393000.0 in Q4 2025.
Entera Bio (ENTX) Total Debt (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has 3 years of Total Debt data on file, last reported at $567000.0 in Q1 2026.
- Quarterly Total Debt rose 10.1% year-over-year to $567000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $567000.0 (up 10.1% YoY) and the FY2025 annual result came in at $393000.0, changed N/A from the prior year.
- Total Debt climbed to $567000.0 in Q1 2026, from $393000.0 in the prior quarter.
- In the past five years, Total Debt ranged from a high of $567000.0 in Q1 2026 to a low of $393000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.34 Bn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | 284,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 284,000.00 |
| Mar 31, 2026 | 567,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Sep 30, 2025 | 527,000.00 |
| Jun 30, 2025 | 524,000.00 |
| Mar 31, 2025 | 515,000.00 |
| Dec 31, 2017 | 3.89 Mn |